Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Drugs Affecting Neurotransmitter Synthesis
Human Genetics
Pharmacogenetics of Drug Metabolism: Overview
Neural Regulation
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 21, 2026

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
Published on: August 10, 2012
Elizabeth S Barrie1, David Weinshenker1, Anurag Verma1
1From the Center for Pharmacogenomics, College of Medicine, The Ohio State University, Columbus (E.S.B., J.K.P., W.S.); Department of Human Genetics, Emory University School of Medicine, Atlanta, GA (D.W., J.F.C.); Center for Systems Genomics, Pennsylvania State University, University Park (A.V., S.A.P., M.D.R.); Department of Genetics, University of North Carolina School of Medicine, Chapel Hill (L.A.L.); Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson (J.G.W.); The Sigfried and Janet Weis Center for Research, Geisinger Health System, Danville, PA (H.K., G.T., D.J.C.); Institute for Personalized Medicine, The Pennsylvania State University College of Medicine, Hershey (G.S.G.); Center for Human Genetics, Marshfield Clinic Research Foundation, WI (M.H.B., S.J.H.); and Department of Psychology, The University of Chicago, IL (G.J.N.).
Genetic variants in dopamine β-hydroxylase (DBH) significantly impact its expression in the liver and lung, influencing sympathetic tone and potentially protecting against heart attack.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: